Roche Diagnostics Imidazolium Reagent Mass Spectrometry Patent Grant

The USPTO issued Patent US12600700B2 to Roche Diagnostics Operations, Inc. covering imidazolium compounds for mass spectrometry applications and methods of mass spectrometric determination of analyte molecules. The patent names nine inventors and contains 14 allowed claims under CPC classifications G01N 33/58 and C07D 233/02.\n\nManufacturers and researchers developing mass spectrometry reagents or analytical methods involving imidazolium compounds should review this patent to assess potential infringement exposure. Companies in the pharmaceutical, diagnostic, and analytical chemistry sectors may need to evaluate whether their current or planned products fall within the scope of these claims and determine whether licensing from Roche is necessary.